SCHEMBL1633796

SCHEMBL1633796

CCOC(=O)C1CC12CC1CCCC12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.35
ALDH1A1 P00352 7/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
PPM1B O75688 1/20 0.33
PTPN1 P18031 1/20 0.33
PPP1CC P36873 1/20 0.33
TLR4 O00206 1/20 0.33
POLB P06746 1/20 0.33
KDM4E B2RXH2 2/20 0.32
LMNA P02545 1/20 0.32
MEN1 O00255 1/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
KMT2A Q03164 1/20 0.32
HSD17B10 Q99714 1/20 0.32
FPR2 P25090 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1635993 0.74 PPM1B (0.36) MAPTALDH1A1CYP3A4CYP2D6CYP2C9
SCHEMBL294716 0.72 LMNA (0.43) MAPTALDH1A1CYP3A4CYP2D6CYP2C9
SCHEMBL1634132 0.69 CYP3A4 (0.40) MAPTALDH1A1CYP3A4CYP2D6CYP2C9
SCHEMBL6410025 0.69 PPM1B (0.49) MAPTALDH1A1PPM1BPTPN1PPP1CC
SCHEMBL30148845 0.68 PPM1B (0.39) MAPTALDH1A1CYP3A4CYP2D6CYP2C9
SCHEMBL1634761 0.68 ALDH1A1 (0.37) MAPTALDH1A1CYP3A4CYP2D6CYP2C9
SCHEMBL17118105 0.67 MAPT (0.41) MAPTALDH1A1CYP3A4CYP2D6CYP2C9
SCHEMBL1634432 0.67 FPR3 (0.31) FPR2
SCHEMBL3691417 0.66 ALDH1A1 (0.47) MAPTALDH1A1CYP3A4CYP2D6CYP2C9
SCHEMBL6574520 0.66 MAPT (0.40) MAPTALDH1A1CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932245-B2 Spirocyclopropyl amides and acids and their therapeutic applications ABBOTT LABORATORIES (US) 2011-04-26 US disclosed
EP-1558230-B1 SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20040204396-A1 Spirocyclopropyl amides and acids and their therapeutic applications ABBVIE INC. 2004-10-14 US disclosed
US-20040077616-A1 Spirocyclopropyl amides and acids and their therapeutic applications ABBOTT LABORATORIES 2004-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077616-A1 Spirocyclopropyl amides and acids and their therapeutic applications SCN1A, SCN1B, SCN10A MAPT 778/4885ALDH1A1 85/4885CYP3A4 1668/4885
US-20040204396-A1 Spirocyclopropyl amides and acids and their therapeutic applications SCN1A, SCN1B, SCN10A MAPT 778/4885ALDH1A1 85/4885CYP3A4 1668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.